TrialTargeted oncology2017

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Jean-Luc Van Laethem et al.PubMed ↗Publisher ↗

No numbers read from the abstract.